Recep Demirci

Dr. Recep Demirci


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2021 in Seminars in Dialysis
Verified
Journal Article
Open access
PDF file
CSCan Sevinc
Can Sevinc
RDRecep Demirci
Recep Demirci
OTOzge Timur
Ozge Timur
Various risk scores such as COVID‐GRAM Critical Illness Risk Score (COVID‐GRAM), quick COVID‐19 Severity Index (qCSI), and systemic immune‐inflammation index (SII) have been developed to determine critical illness in hospitalized patients. None of these risk scoring systems was evaluated in HD patients who indeed carry the highest risk of developing critical illnesses. We aimed to evaluate, in hemodialysis (HD) patients with COVID‐19, the performance of these scoring systems for the need of intensive care unit (ICU) and mortality. The qCSI, COVID‐GRAM, and SII scores of the patients at admission to hospital were calculated and grouped according to the scoring results. The primary outcome of the study was mortality and need of ICU. Critical illness was described as a composition of admission to the ICU, invasive ventilation, or death. It was determined that when the qCSI is over 6.5, the need for ICU increased 13.8 times and mortality increased 21.3 times. When the COVID‐GRAM score is >157, the ICU need increased 14.7 times and the mortality increased 33.7 times. We found that the need for ICU increased 4.2 times and mortality increased 3.1 times when the SII score was >1145. These tests, which can be easily calculated, could be used to estimate the risk of developing critical illness among COVID‐19 HD patients. Estimating the risk of critical illness could help to reduce mortality in HD patients.

11 September 2015 in Renal Failure
Verified
Journal Article
Open access
PDF file
MAMehmet Fatih Akdoğan
Mehmet Fatih Akdoğan
AAAlper AZAK
Alper AZAK
NDNazım Denizli
Nazım Denizli
BHBülent Huddam
Bülent Huddam
GKGülay Koçak
Gülay Koçak
MDMurat Duranay
Murat Duranay
Purpose: Patients diagnosed with chronic kidney disease (CKD) have a greater rate of cardiovascular mortality when compared with the general population. The soluble form of TNF-like weak inducer of apoptosis (TWEAK) and monocyte chemoattractan protein 1 (MCP-1) play important roles in cellular proliferation, migration and apoptosis. The current study aimed to analyze whether soluble TWEAK (sTWEAK) and MCP-1 levels are associated with the severity of coronary arterial disease (CAD) in CKD patients. Methods: Ninety-seven patients diagnosed with CKD stages 2–3 according to their estimated glomerular filtration rate and the presence of kidney injury were included in the study. Plasma sTWEAK and MCP-1 concentrations were determined using commercially available ELISA kits. Coronary angiographies were performed through femoral artery access using the Judkins technique. Results: Correlation analysis of sTWEAK and Gensini scores showed significant association (p < 0.01, r2 = 0.287). Also significant correlation has been found in MCP-1 levels and Gensini scores (p < 0.01, r2 = 0.414). When patients were divided into two groups with a limit of 17 according to their Gensini score, sTWEAK levels indicated a statistically significant difference (p < 0.01). Conclusions: Our findings support a relationship between sTWEAK and MCP-1 levels and CAD in CKD stages 2–3 patients.

1 September 2021 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
RDRecep Demirci
Recep Demirci
CSCan Sevinc
Can Sevinc
Aim: Vascular calcification is a common complication in CKD. Studies conducted in patients with end-stage renal disease (ESRD) showed that calcification in vascular structures is an important component of the atherosclerosis process. GLA rich protein (GRP) has been suggested as a potential marker for vascular calcification. We investigated the relationship between GRP levels, carotid intima media thickness and inflammatory parameters in patients with predialysis stage 3, 4 and 5 CKD. Material and Methods: A total of 106 patients aged ≥ 18 years with CKD stage 3, stage 4 and non-dialysis stage 5 and 25 healthy volunteers were enrolled in the study. Patients with obesity, uncontrolled hypertension, coronary artery disease, with active cancer or liver disease, malignant hematologic disorders, acute renal failure, acute or chronic infections were excluded. As the control group, healthy volunteers without any known illness, regular drug use, smoking, alcohol use, and obesity were recruited. Results: Patients were divided into two groups as those with CIMT below 0.90 mm and those with CIMT 0.90 mm and above. There was no significant difference between the two groups in terms of the presence of HT and DM. While the CRP values of the group with high CIMT were found to be significantly higher (p=0.005), the GLA rich protein levels of this group were found to be significantly higher (p=0.019). Conclusion: In our study, it was determined that there was a positive correlation between GRP levels and CIMT in patients with predialysis CKD, and GRP levels were higher in patients with CIMT above 0.90 mm. These findings suggest that GRP levels can be used as a cardiovascular event biomarker in patients with CKD.

17 June 2021 in The Journal of Vascular Access
Verified
Journal Article
Closed access
PDF file
RDRecep Demirci
Recep Demirci
BSBerrak Sahtiyancı
Berrak Sahtiyancı
ABAli Bakan
Ali Bakan
OAOkan Akyuz
Okan Akyuz
Here we aimed to investigate the predictors of catheter-related bloodstream infections (CRBSI) in patients with acute kidney injury or chronic kidney disease who required renal replacement therapy through a non-tunneled hemodialysis catheter. A total of 111 patients who received non-tunneled hemodialysis catheters were retrospectively evaluated. Patients were divided into two groups; those who developed CRBSI and those who did not. Patient’s demographic data, laboratory results at admission, information regarding catheter infections, and culture results were obtained from electronic medical records. The mean age of the patients was 64 ± 16 years, and 51 of them were male. CRBSI occurred in 14 patients (12.6%). Admission serum albumin level (OR: 0.119, 95% CI: 0.019–0.756, p = 0.024), admission mean platelet volume (OR: 2.207, 95% CI: 1.188–4.100, p = 0.012) and catheter duration (OR: 1.580, 95% CI: 1.210–2.064, p = 0.001) were independent predictors for the CRBSI development. ROC curve analysis demonstrated that a catheter duration of 22 days was predictive for presence of CRBSI (78% sensitivity, 76% specificity, AUC: 0.825, 95% CI: 0.724–0.925, p < 0.001). Prolonged catheter duration, low serum albumin, and high mean platelet volume independently predict the development of CRBSI in patients undergoing hemodialysis for acute kidney injury or chronic kidney disease.

19 September 2021 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
OAOkan Akyüz
Okan Akyüz
MGMurat Gücün
Murat Gücün
RDRecep Demirci
Recep Demirci
Mehmet CelikMehmet Celik
Mehmet Celik

Verified
Journal Article
Open access
PDF file
ÖYÖZGÜR YILMAZ
ÖZGÜR YILMAZ
OEOsman Erinc
Osman Erinc
OIOzan Cemal Icacan
Ozan Cemal Icacan
GEGulseren Goktolga Erkoca
Gulseren Goktolga Erkoca
RDRecep Demirci
Recep Demirci
AAAkarsu Akarsu
Akarsu Akarsu
Background and Objectives: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease characterized by recurrent inflammatory attacks and a risk of AA amyloidosis. Although inflammatory activity may persist during attack-free periods, reliable biomarkers of subclinical inflammation remain limited. The pan-immune-inflammation value (PIV), a composite index derived from circulating immune cell counts, has emerged as a marker of systemic inflammation. This study investigated the association between PIV, MEFV mutation burden, and amyloidosis in patients with FMF during attack-free periods. Materials and Methods: This retrospective cross-sectional study included 386 adult patients with FMF followed at a tertiary rheumatology clinic. Patients were stratified by MEFV mutation status into three groups: Group 1 (genetically non-confirmatory FMF or low-penetrance/non-causative MEFV variants such as E148Q), Group 2 (single pathogenic mutation), and Group 3 (biallelic pathogenic mutations). Patients were also categorized by amyloidosis status. PIV was calculated as (neutrophil count × platelet count × monocyte count)/lymphocyte count using complete blood count parameters obtained during attack-free visits. Associations between PIV and clinical characteristics were evaluated using correlation and logistic regression analyses, and discriminative performance was assessed using receiver operating characteristic (ROC) curve analysis. Statistical significance was set at p < 0.05. Results: PIV levels differed significantly across genotype-defined groups (median: 172, 329.3, and 479.5 in Groups 1–3, respectively; p < 0.001) and were higher in patients with amyloidosis than in those without amyloidosis (540.5 vs. 218.1; p < 0.001). In multivariable logistic regression analysis, PIV remained independently associated with both biallelic pathogenic mutation status (OR = 1.007, 95% CI: 1.003–1.010, p < 0.001) and the presence of amyloidosis (OR = 1.002, 95% CI: 1.001–1.003, p < 0.001). ROC analysis showed an AUC of 0.853 for distinguishing Group 3 from Group 1 (cut-off 337; sensitivity 80.7%, specificity 77.0%) and an AUC of 0.814 for discriminating patients with and without amyloidosis (cut-off 316.4; sensitivity 86.0%, specificity 65.6%). Conclusions: PIV was independently associated with MEFV mutation burden and amyloidosis in patients with FMF during attack-free periods. These findings suggest that PIV may reflect the inflammatory burden associated with genetic mutation load and amyloidosis in FMF. Prospective longitudinal studies are warranted to externally validate these findings and further clarify the relationship between PIV, inflammatory burden, and disease severity in FMF.